Addex Therapeutics Ltd.

Addex Therapeutics Ltd. is a pharmaceutical company that specializes in the development of innovative treatments based on allosteric modulation of G-protein coupled receptors (GPCRs). GPCRs are a significant area of interest in drug discovery due to their pivotal role in many physiological processes and their prevalence in potential therapeutic targets. Addex leverages its proprietary technology to discover and develop small-molecule drugs aimed at neurological and other central nervous system disorders. The company's commitment to advancing allosteric modulators positions it uniquely in the biopharmaceutical industry, addressing unmet medical needs in areas such as anxiety, epilepsy, Parkinson's disease, and schizophrenia. Addex’s focus on allosteric modulators, which offer advantages over traditional orthosteric drugs by providing more selective action with potentially fewer side effects, underscores its innovative approach. As a player in the biotech and pharmaceutical sectors, Addex Therapeutics Ltd. contributes to the evolving landscape of medical treatments, aiming to improve patient outcomes through pioneering science and collaboration with global healthcare partners.